Woman before and after Dysport treatment
Frown Before
Dysport
Treatment
After 50 units,
Day 14 — Individual
results may vary.
FOR HEALTHCARE PROFESSIONALS

Dysport®
(abobotulinumtoxinA) for the temporary treatment of moderate to severe glabellar lines

SEE THE RESULTS

When 130,000 patients took the Dysport Challenge, 97% of Dysport users said they'd use it again.5

Rapid Onset & Enduring Efficacy

More than half of patients saw improvement in as little as 2-3 days,1-3* and results may last up to 4 months.

LEARN MORE


Dysport Reconstitution

View dilution chart for the treatment of moderate to severe glabellar lines.

SEE RECONSTITUTION GUIDELINES

Find a doctor

FIND A SPECIALIST FEATURE

Gain patients from DysportUSA.com through our complimentary Find a Specialist feature. Conditions apply.

ABOUT FIND A SPECIALIST LISTINGS

injectable rewards

GET REWARDED

Make every order count by joining ASPIRE Galderma Rewards, the program that offers physicians faster ways to earn instant savings, product discounts, and quarterly rebates. Not only that, but the program is designed to enhance your practice by enabling loyal patients to redeem their own ASPIRE Galderma Rewards with you!

JOIN NOW

*A secondary endpoint based on Kaplan-Meier estimates the cumulative rate of time to onset of response. The median time to onset of response was 3 days in GL-1 (Dysport 55/105 [52%], Placebo 3/53 [6%] and GL-2 (Dysport 36/71 [51%], Placebo 9/71 [13%]), and 2 days in GL-3 (Dysport 110/200 [55%], Placebo 4/100 [4%]).1-3

†GL-1 and GL-3 evaluated subjects for at least 150 days following treatment. Based on investigator assessment, response was maintained for up to 4 months in both GL-1 (Dysport 24/105 [23%], Placebo 2/53 [4%]) and GL-3 (Dysport 58/200 [29%], Placebo 1/100 [1%]).2-4

References
  1. Additional study information for GL-2: Data on file, Galderma Laboratories, L.P.
  2. Additional study information for GL-3: Data on file, Galderma Laboratories, L.P.
  3. Additional study information for GL-1: Data on file, Galderma Laboratories, L.P.
  4. Dysport for Injection Package Insert. Scottsdale, Arizona. Galderma Laboratories, L.P.; July 2015.
  5. Dysport Challenge. Data on file. Galderma Laboratories, L.P.

IMPORTANT SAFETY INFORMATION

Indication: Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

DOSAGE AND ADMINISTRATION

The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

WARNINGS AND PRECAUTIONS

Facial Anatomy in the Treatment of Glabellar Lines

Pre-existing Neuromuscular Disorders

Human Albumin

Intradermal Immune Reaction

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information, including Medication Guide.